Halozyme Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Diego, CA
HALO chart
What traders are saying about $HALO
Latest postsHalozyme Therapeutics, Inc. news
- Halozyme Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-11-10
Seeking Alpha ·
- Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Yahoo Finance ·
- TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
Yahoo Finance ·
- NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump
Yahoo Finance ·
- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%
Yahoo Finance ·
- Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
Yahoo Finance ·
- HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
Yahoo Finance ·
- 5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
Benzinga ·
- Weekly Recap: Q3 earnings growth and RYBREVANT FASPRO FDA approval
TradingView ·
- Leerink Partners downgrades Halozyme Therapeutics to Market Perform from Outperform
TradingView ·
- Halozyme Therapeutics Stock Price Forecast. Should You Buy HALO?
StockInvest.us ·
- $HALO stock is down 16% today. Here's what we see in our data.
Quiver Quantitative ·
Halozyme Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 |
| Total assets (year end) | $2.53B | $2.06B | $1.73B | $1.84B |
| Cash and equivalents (year end) | $133.8M | $115.8M | $118.4M | $234.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Halozyme Therapeutics, Inc.
- Ticker
- HALO (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1159036
- Former names
- HALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC
Frequently asked questions
What exchange is Halozyme Therapeutics, Inc. listed on?
Halozyme Therapeutics, Inc. trades on the Nasdaq under the ticker symbol HALO.
What industry is Halozyme Therapeutics, Inc. in?
Halozyme Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Halozyme Therapeutics, Inc. headquartered?
Halozyme Therapeutics, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Halozyme Therapeutics, Inc.'s fiscal year end?
Halozyme Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Halozyme Therapeutics, Inc. report?
Halozyme Therapeutics, Inc. reported $1.40B in revenue for calendar year 2025, according to its SEC filings.